The Latest Cardiac and Vascular News
– LYPDISO™ demonstrated a statistically significant 46% relative percent increase in EPA change from baseline over Vascepa® – – LYPDISO™ demonstrated a 39% relative difference in response over Vascepa in TG reduction – – Primary endpoint of percent change from baseline to end of treatment in triglycerides in the pharmacodynamic population did not meet […]
BAUDETTE, Minn.–(BUSINESS WIRE)–ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced the launch of Prazosin HCl Capsules USP, 1mg and 2mg, following the U.S. Food and Drug Administration’s (“FDA”) approval of the Company’s prior approval supplement application (“PAS”). The current annual U.S. market for Prazosin 1mg and 2mg […]
GENT, Belgium–(BUSINESS WIRE)–FEops, a digital health leader in personalized predictive planning for structural heart interventions, is proud to announce having modeled 2000 patients with FEops HEARTguide™ for the pre-operative planning of structural heart interventions. FEops HEARTguide™ is currently commercially available in the European Union, Canada and Australia for its TAVI […]
The application includes data from the STTAR clinical study with a one-year follow-up period. NEWTOWN, Pa. Jan. 29, 2021 / PRNewswire / – Micro Interventional Devices, Inc. ™ (MID) announced today that it has provided the technical documentation required for CE approval of its MIA-T ™ Percutaneous Tricuspid Annuloplasty System for tricuspid valve […]
Positive opinion is based on extensive clinical study results, including results of the REDUCE-IT® cardiovascular outcomes study European Commission decision on the Marketing Authorisation Application expected in April 2021 DUBLIN, Ireland and BRIDGEWATER, N.J., Jan. 29, 2021 (GLOBE NEWSWIRE) — Amarin Corporation plc (NASDAQ:AMRN) today announced that in response to Amarin’s […]
Filing includes one year-follow up data from the STTAR Clinical Study. NEWTOWN, Pa., Jan. 28, 2021 /PRNewswire/ — Micro Interventional Devices, Inc.™ (MID) announced today that it has submitted the required technical documentation for CE Mark approval for its MIA-T™ Percutaneous Tricuspid Annuloplasty System for tricuspid valve repair to its Notified Body. The receipt of a […]
WINNIPEG, MB, Jan. 27, 2021 /PRNewswire/ – Medicure Inc. (“Medicure” or the “Company”) (TSXV: MPH) (OTC: MCUJF), a cardiovascular pharmaceutical company, is pleased to announce the early completion of iSPASM, a randomized, double-blind, single-center, Phase 1/2a trial aimed at assessing the safety of long-term (7-day) use of AGGRASTAT® (tirofiban hydrochloride) injection (an intravenous GP IIb/IIIa […]
Available for collaborations, analytics, and licensing for faster, more cost-effective access to research-grade heart failure data BOSTON, Jan. 28, 2021 /PRNewswire/ — OM1, a leading real-world data (RWD), outcomes and technology company with a focus on chronic diseases, today announced the launch of an expanded Heart Failure registry. Heart Failure (HF) is considered […]
Cardiovascular disease remains a leading cause of mortality in both the European Union and globally, with antiplatelet therapy being a core treatment to prevent cardiovascular events The lack of reversal agents for patients taking antiplatelet therapies who require urgent surgery or experience a major bleeding event remains a critical unmet need […]
EDEN PRAIRIE, Minn., Jan. 28, 2021 (GLOBE NEWSWIRE) — CHF Solutions (Nasdaq: CHFS), a medical device company dedicated to changing the lives of patients suffering from fluid overload, today announced key takeaways from its physician-led webinar discussing real-world experience using ultrafiltration (UF) in the management of heart failure patients. Panelists […]
